The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1696
February 19, 2024
View Complete Issue         Table of Contents 2019 
Issue 1696
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease
February 19, 2024 (Issue: 1696)
The FDA has approved daprodustat (Jesduvroq – GSK), a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for oral treatment of anemia due to chronic kidney disease (CKD) in adults who have been on dialysis for at least 4 months....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1696
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.